In the POWER 1 and 2 studies.

In the POWER 1 and 2 studies, adult patients were randomized to PREZISTA and ritonavir twice daily plus an individualized combination of anti-HIV drugs called an optimized background regimen or commercially available investigator selected protease inhibitors boosted with ritonavir plus OBR .

This indication is based on Week 24 analyzes of plasma HIV RNA levels and CD4+ cell counts based on two controlled trials of PREZISTA / rtv in combination with other antiretrovirals. Both studies were advanced in clinical, treatment-experienced conducted in adult patients with evidence of HIV – 1 replication despite ongoing antiretroviral therapy.Children aged between 5 years ago may learning how to Use this a computer mouse, new research suggests.

Lane conducted the study with Jenny Ziviani of University of Queensland in Brisbane, Australia. Their findings appears in the latest edition the magazine Computer & Education.

Other entries from category "reports":

Tag Cloud